Mounjaro, Zepbound shortages expected to continue through June, FDA says

The shortage of Eli Lilly’s popular diabetes drug Mounjaro will continue through June of this year for all but one strength due to increased demand for the drug. Previously, FDA had estimated that Mounjaro would be in limited availability through this month. In addition, most strengths of the company's other tirzepatide drug, Zepbound, are also in short supply. FDA reports that only the 2.5 mg/0.5 mL strengths of both drugs are currently available.